Drugs / MatriPlax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05886985 | Dec 2023 → Dec 2026 expected | acute respiratory distress syndrome | BioSpring Medical Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MatriPlax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05886985 ↗ |
| Modality | Cell therapy | “MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells)” NCT05886985 ↗ |
| Route | Intravenous | “will be given intravenously on Day 1 and Day 4” NCT05886985 ↗ |